Review




Structured Review

JCRB Cell Bank human pdac cell lines panc-1
Human Pdac Cell Lines Panc 1, supplied by JCRB Cell Bank, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pdac+tissue+array/panc+1/pm38104546-67-1-14
Average 90 stars, based on 1 article reviews
human pdac cell lines panc-1 - by Bioz Stars, 2026-11
90/100 stars

Images

Related Articles

other:

Article Title: Cancer-associated fibroblasts reuse cancer-derived lactate to maintain a fibrotic and immunosuppressive microenvironment in pancreatic cancer.
Article Snippet: The human pancreatic cancer cell lines PK8 and PANC-1 were obtained from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan) and the RIKEN Bio-Resource Center Cell Bank (Ibaraki, Japan).

Article Title: Expression of kinesin family member C1 in pancreatic ductal adenocarcinoma affects tumor progression and stemness.
Article Snippet: The human pancreatic ductal adenocarcinoma-derived cell lines PANC-1, PK-1, KP-4, and T3M-4 were purchased from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Article Title: Catalase-Knockout Complements the Radio-Sensitization Effect of Titanium Peroxide Nanoparticles on Pancreatic Cancer Cells
Article Snippet: Titanium dioxide (TiO 2 ) NPs (STS-01, Ishihara Sangyo Kaisha, Osaka, Japan) were surface-modified with PAA (MW 5000, Wako Pure Chemical Industries Ltd., Osaka, Japan) via a hydrothermal process.

Article Title: A glypican-1-targeted antibody-drug conjugate exhibits potent tumor growth inhibition in glypican-1-positive pancreatic cancer and esophageal squamous cell carcinoma
Article Snippet: Two human pancreatic cancer cell lines, namely BxPC-3 (RRID:CVCL_0186) and PK-8 (RRID:CVCL_4718) were obtained from the European Collection of Authenticated Cell Cultures, the Japanese Collection of Research Bioresources (Osaka, Japan), and RIKEN BioResource Center (Wako, Japan), respectively.

Article Title: IQ motif containing GTPase activating protein 3 is associated with cancer stemness and survival in pancreatic ductal adenocarcinoma.
Article Snippet: The human PDAC cell lines PANC-1, PK-1, KP-4, and T3M-4 were purchased from the Japanese Collection of Research Bioresources Cell Bank (Osaka, Japan).

Article Title: Photosensitizer verteporfin inhibits the growth of YAP- and TAZ-dominant gastric cancer cells by suppressing the anti-apoptotic protein Survivin in a light-independent manner
Article Snippet: Kato III (derived from a signet ring cell carcinoma with no further information), NUGC-4 (derived from an adenocarcinoma, poorly differentiated, signet ring cell carcinoma with lymph node metastasis in a 32-year-old female), MKN-45-Luc (derived from a poorly differentiated adenocarcinoma in a 62-year-old female), MKN-74/CMV-Luc cells (derived from a moderately differentiated tubular adenocarcinoma with liver metastasis in a 37-year-old male), and PANC-1 (TAZ-dominant pancreatic cancer cell line) were obtained from the JCRB Cell Bank.

Cell Culture:

Article Title: Catalase-Knockout Complements the Radio-Sensitization Effect of Titanium Peroxide Nanoparticles on Pancreatic Cancer Cells.
Article Snippet: Particle sizes and zeta potentials were determined using a Zetasizer Nano ZS (Malvern Instrument Ltd., Malvern, UK). .. The human pancreatic cancer cell line, PANC-1, was obtained from the JCRB Cell Bank (Osaka, Japan) and cultured in a complete medium consisting of Dulbecco’s modified Eagle medium (DMEM) High Glucose (Nacalai Tesque, Inc., Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic solution (100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B). ..

Modification:

Article Title: Catalase-Knockout Complements the Radio-Sensitization Effect of Titanium Peroxide Nanoparticles on Pancreatic Cancer Cells.
Article Snippet: Particle sizes and zeta potentials were determined using a Zetasizer Nano ZS (Malvern Instrument Ltd., Malvern, UK). .. The human pancreatic cancer cell line, PANC-1, was obtained from the JCRB Cell Bank (Osaka, Japan) and cultured in a complete medium consisting of Dulbecco’s modified Eagle medium (DMEM) High Glucose (Nacalai Tesque, Inc., Kyoto, Japan) supplemented with 10% fetal bovine serum (FBS) and 1% antibiotic solution (100 U/mL penicillin, 100 μg/mL streptomycin, and 0.25 μg/mL amphotericin B). ..



Similar Products

86
Biomax Inc human pdac tissue array
(A) Representative IHC staining <t>of</t> <t>ITGB3</t> in <t>PDAC</t> tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.
Human Pdac Tissue Array, supplied by Biomax Inc, used in various techniques. Bioz Stars score: 86/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pdac+tissue+array/array+slides+tissue/bio_rxiv__64898__2026__01__15__699725-59-16-21
Average 86 stars, based on 1 article reviews
human pdac tissue array - by Bioz Stars, 2026-11
86/100 stars
  Buy from Supplier

90
TissueArray.com LLC human pdac tissue array
(A) Representative IHC staining <t>of</t> <t>ITGB3</t> in <t>PDAC</t> tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.
Human Pdac Tissue Array, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+array/pm39048609-54-1-9
Average 90 stars, based on 1 article reviews
human pdac tissue array - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
TissueArray.com LLC the human pdac tissue array
STING expression in <t>human</t> <t>PDAC</t> stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.
The Human Pdac Tissue Array, supplied by TissueArray.com LLC, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+array/pmc11269671-39-1-9
Average 90 stars, based on 1 article reviews
the human pdac tissue array - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
U.S Biomax Inc human pdac tissue array
<t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
Human Pdac Tissue Array, supplied by U.S Biomax Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pdac+tissue+array/human+pancreatic+cancer+tissue+arrays/pmc10280815-636-7-11
Average 90 stars, based on 1 article reviews
human pdac tissue array - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
Pantomics Inc human pancreas cancer tissue array including 20 pdacs
<t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
Human Pancreas Cancer Tissue Array Including 20 Pdacs, supplied by Pantomics Inc, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pdac+tissue+array/pancreatic+cancer+tissue+array/pmc09763154-101-8-15
Average 90 stars, based on 1 article reviews
human pancreas cancer tissue array including 20 pdacs - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

90
BioChain Institute human pdac tissue array
<t>a,</t> <t>Immunohistochemistry</t> staining of LPAR4 in a <t>PDAC</t> tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.
Human Pdac Tissue Array, supplied by BioChain Institute, used in various techniques. Bioz Stars score: 90/100, based on 1 PubMed citations. ZERO BIAS - scores, article reviews, protocol conditions and more
https://www.bioz.com/product/human+pdac+tissue+array/Monkey+Tissue+Array+-+22+types+of+cyno+monkey+normal+tissues+covering+all+major+organs/pmc07766822-273-13-17
Average 90 stars, based on 1 article reviews
human pdac tissue array - by Bioz Stars, 2026-11
90/100 stars
  Buy from Supplier

Image Search Results


(A) Representative IHC staining of ITGB3 in PDAC tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.

Journal: bioRxiv

Article Title: ProAgio, a Novel Integrin αvβ3 Targeted Cytotoxin, Suppresses Tumor Growth and Reprograms the PDAC Microenvironment

doi: 10.64898/2026.01.15.699725

Figure Lengend Snippet: (A) Representative IHC staining of ITGB3 in PDAC tissue microarrays (TMA) showing varying expression levels in non-cancer and cancer tissue sections. (B). High magnification IHC images demonstrating the expression of ITGB3 on normal pancreas and cancer cells with stromal regions. (D-I) . Scatter plots depicting the correlation between ITGB3 and key tumor-associated markers such as HIF-1α (D) , GLUT-1 (E) , VEGFA (F) , Vimentin (G) , COL1A1 (H) , and PECAM1 (I) . Pearson correlation coefficients (R) and p -values indicate statistically significant positive correlation between ITGB3 and these markers. Statistical significance was assessed using a two-tailed unpaired Student’s t-test. All quantitative data represent the mean ± SEM. ∗∗∗∗p < 0.0001.

Article Snippet: To evaluate the role of ITGB3 in PDAC, we analyzed its expression using IHC in a human PDAC tissue array (PA483-L97, Biomax) that contains 40 cancer and eight non-cancer tissues ( Supplementary Table 1 ).

Techniques: Immunohistochemistry, Expressing, Two Tailed Test

STING expression in human PDAC stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.

Journal: Scientific Reports

Article Title: Activation of STING in pancreatic cancer-associated fibroblasts exerts an antitumor effect by enhancing tumor immunity

doi: 10.1038/s41598-024-68061-y

Figure Lengend Snippet: STING expression in human PDAC stroma and CAFs. ( a ) Groups categorized by positive, weakly positive, and negative STING expression in PDAC stroma. Representative IHC analysis of STING using a human PDAC tissue array (scale bar, 100 μm). ( b ) Percentages of the indicated groups in 40 PDAC samples. ( c ) Co-immunofluorescence staining for α-SMA (red) and STING (green) in STING positive or weakly positive or negative in stroma. ( d ) 5-AZA (0.1 nM) was administered to CAF1 and CAF2 derived from murine PDACs and incubated for 24 h.

Article Snippet: The human PDAC tissue array was purchased commercially from TissueArray.com (No.PA482a).

Techniques: Expressing, Immunofluorescence, Staining, Derivative Assay, Incubation

a, Immunohistochemistry staining of LPAR4 in a PDAC tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.

Journal: Nature cell biology

Article Title: Pancreatic cancer cells upregulate LPAR4 in response to isolation stress to promote an ECM-enriched niche and support tumor initiation

doi: 10.1038/s41556-022-01055-y

Figure Lengend Snippet: a, Immunohistochemistry staining of LPAR4 in a PDAC tissue array consisted of 15 PDAC samples and 4 samples of normal pancreas. Scale bar is 50 μM. Representative images showing normal pancreas (n=4 biological samples), low-LPAR4 PDAC (n=9 biological samples), and high-LPAR4 PDAC (n=6 biological samples). Bar graph shows the relative percentage of LPAR4-low and LPAR4-high patients in the PDAC tissue array. b, Quantitative RT-PCR confirming the manipulation of LPAR4 expression in 2 pancreatic cancer cell lines (Colo-357, MIA PaCa-2) and 2 patient-derived cancer cells (79E, 34E). Data were shown as mean ± s.d. (n=4 independent experiments for Colo-357 and 79E cells with LPAR4 stable knockdown, n=3 for Colo-357, 79E, and MiaPaCa2 cells with LPAR4 ectopic expression, n=3 for 34E cells with LPAR4 stable knockdown, and n=4 for 34E with LPAR4 ectopic expression). c, Non-invasive Bioluminescence images showing tumors formed at day 10 for Colo-357+sh-CTRL+luciferase or Colo-357+sh-R4.1+luciferase of various number implanted in the pancreas of nu/nu mice. Right panel showing the luminescence intensity in a blue-to-red spectrum. d, f, Trypan blue exclusion assay showing the relative number of viable cells with or without LPAR4 expression manipulation grown in 10% serum and 2D at day 4 and day 7. e, Tumor growth rates for 1 million Colo-357 cells with or without LPAR4 expression manipulation in a subcutaneous tumor model. Data were presented as mean ± s.d. for n=8 independent samples for each group. g, Quantitative RT-PCR confirming the knockdown of LPAR1 in Colo-357 cells. h, Effects of LPAR1 knockdown using siRNA on 2D or 3D (methylcellulose sphere forming) cell growth. Data were presented as mean ± s.d. for n=3 independent experiments (d,f,g, and h). Statistical analyses were performed using two tailed unpaired one sample t-test (b,g, and h) and one-way ANOVA (d-f). Source numerical data are available in source data.

Article Snippet: Immunohistochemistry staining of LPAR4 or FN1 in human PDAC tissue array (US Biomax PA484a) or formalin-fixed, paraffin-embedded xenograft tumors were performed using the LPAR4 antibody (Thermo Fisher, #PA5–49727) or FN1 antibody (CST, #26836, E5H6X) following the manufacturer’s protocol.

Techniques: Immunohistochemistry, Staining, Quantitative RT-PCR, Expressing, Derivative Assay, Luciferase, Trypan Blue Exclusion Assay, Two Tailed Test